14.25 USD
-1.28 (-8.26%)
We assign a fundamental rating of 2 out of 10 to BNR. BNR was compared to 533 industry peers in the Biotechnology industry. BNR may be in some trouble as it scores bad on both profitability and health. BNR is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year BNR has reported negative net income.
BNR had a negative operating cash flow in the past year.
In the past 5 years BNR always reported negative net income.
In the past 5 years BNR always reported negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -17.00%, BNR is in the better half of the industry, outperforming 78.61% of the companies in the same industry.
BNR has a Return On Equity of -24.86%. This is amongst the best in the industry. BNR outperforms 80.11% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -17% | ||
| ROE | -24.86% | ||
| ROIC | N/A |
ROA(3y)-54.4%
ROA(5y)-43.17%
ROE(3y)-76.2%
ROE(5y)-58.25%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
BNR has a Gross Margin of 72.12%. This is amongst the best in the industry. BNR outperforms 82.55% of its industry peers.
BNR's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for BNR so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 72.12% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.68%
GM growth 5Y-0.38%
2. Health
2.1 Basic Checks
BNR does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, BNR has about the same amount of shares outstanding.
The number of shares outstanding for BNR has been increased compared to 5 years ago.
There is no outstanding debt for BNR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
BNR has an Altman-Z score of -3.61. This is a bad value and indicates that BNR is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -3.61, BNR is in line with its industry, outperforming 45.22% of the companies in the same industry.
BNR has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
BNR's Debt to Equity ratio of 0.00 is in line compared to the rest of the industry. BNR outperforms 47.28% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -3.61 |
ROIC/WACCN/A
WACC7.54%
2.3 Liquidity
A Current Ratio of 3.22 indicates that BNR has no problem at all paying its short term obligations.
BNR has a worse Current ratio (3.22) than 61.54% of its industry peers.
BNR has a Quick Ratio of 2.97. This indicates that BNR is financially healthy and has no problem in meeting its short term obligations.
BNR has a Quick ratio of 2.97. This is in the lower half of the industry: BNR underperforms 61.54% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.22 | ||
| Quick Ratio | 2.97 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 96.17% over the past year.
BNR shows a small growth in Revenue. In the last year, the Revenue has grown by 5.20%.
Measured over the past years, BNR shows a small growth in Revenue. The Revenue has been growing by 6.21% on average per year.
EPS 1Y (TTM)96.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%91.44%
Revenue 1Y (TTM)5.2%
Revenue growth 3Y0.52%
Revenue growth 5Y6.21%
Sales Q2Q%9.61%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
The Revenue is expected to grow by 15.51% on average over the next years. This is quite good.
EPS Next Y-277.41%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year48.35%
Revenue Next 2Y17.89%
Revenue Next 3Y16.85%
Revenue Next 5Y15.51%
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for BNR. In the last year negative earnings were reported.
Also next year BNR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for BNR!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:BNR (11/21/2025, 8:14:33 PM)
14.25
-1.28 (-8.26%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners30.6%
Inst Owner Change-17.12%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap146.19M
Revenue(TTM)536.30M
Net Income(TTM)-140.24M
Analysts80
Price TargetN/A
Short Float %0.62%
Short Ratio1.3
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1.94 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.84 | ||
| P/tB | 1.84 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.99
EYN/A
EPS(NY)-1.01
Fwd EYN/A
FCF(TTM)-1.08
FCFYN/A
OCF(TTM)-1.08
OCFYN/A
SpS7.35
BVpS7.73
TBVpS7.73
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -17% | ||
| ROE | -24.86% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 72.12% | ||
| FCFM | N/A |
ROA(3y)-54.4%
ROA(5y)-43.17%
ROE(3y)-76.2%
ROE(5y)-58.25%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.68%
GM growth 5Y-0.38%
F-Score5
Asset Turnover0.65
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.22 | ||
| Quick Ratio | 2.97 | ||
| Altman-Z | -3.61 |
F-Score5
WACC7.54%
ROIC/WACCN/A
Cap/Depr(3y)26.43%
Cap/Depr(5y)152.99%
Cap/Sales(3y)5.44%
Cap/Sales(5y)15.37%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)96.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%91.44%
EPS Next Y-277.41%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)5.2%
Revenue growth 3Y0.52%
Revenue growth 5Y6.21%
Sales Q2Q%9.61%
Revenue Next Year48.35%
Revenue Next 2Y17.89%
Revenue Next 3Y16.85%
Revenue Next 5Y15.51%
EBIT growth 1Y80.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y80%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y80%
OCF growth 3YN/A
OCF growth 5YN/A
BURNING ROCK BIOTECH LTD-ADR / BNR FAQ
Can you provide the ChartMill fundamental rating for BURNING ROCK BIOTECH LTD-ADR?
ChartMill assigns a fundamental rating of 2 / 10 to BNR.
What is the valuation status of BURNING ROCK BIOTECH LTD-ADR (BNR) stock?
ChartMill assigns a valuation rating of 0 / 10 to BURNING ROCK BIOTECH LTD-ADR (BNR). This can be considered as Overvalued.
What is the profitability of BNR stock?
BURNING ROCK BIOTECH LTD-ADR (BNR) has a profitability rating of 2 / 10.
Can you provide the expected EPS growth for BNR stock?
The Earnings per Share (EPS) of BURNING ROCK BIOTECH LTD-ADR (BNR) is expected to decline by -277.41% in the next year.